欧洲12国14 261例PsA患者起始TNF抑制剂治疗的留存率与应答率:EuroSpA研究
该研究汇总12个欧洲注册库中14 261例生物制剂初治的银屑病关节炎(PsA)患者常规诊疗数据,分析起始TNF抑制剂(TNFi)的留存率与应答率。中位12个月留存率为77%(95%CI 76–78%),注册库间范围为68–90%;6个月DAS28缓解率为56%,ACR20/50/70应答分别为53%/38%/22%。基线特征与结局在不同注册库间存在显著异质性。
要点
- 14 261例生物制剂初治PsA患者起始TNFi,中位12个月留存率为77%(95%CI 76–78%),注册库间范围68–90%。
- 6个月DAS28缓解率56%、DAS28<2.6的LUNDEX调整值为45%;ACR20/50/70应答分别为53%/38%/22%。
- 2009年后起始TNFi且符合CASPAR标准(n=1980)或基线≥1个肿胀关节(n=5803)者,留存与应答率与总体相似。
核心结论
- 在常规诊疗中起始首个TNFi的14 000余例PsA患者中,约半数在6个月时达到DAS28缓解,四分之三在1年时仍在用药。
- 不同注册库间基线特征与结局存在显著异质性,但总体留存与应答率在符合CASPAR标准或基线有肿胀关节的亚组中与总体相似。
研究设计与样本
- 前瞻性收集12个欧洲注册库中PsA患者常规诊疗数据并汇总分析。
- 采用方差分析与两两比较探索注册库间基线特征异质性;以Kaplan-Meier法计算留存率,并计算DAS28缓解、DAPSA≤4及ACR20/50/70应答率,含LUNDEX调整。
主要发现
- 中位12个月留存率为77%(95%CI 76–78%),注册库间范围为68–90%。
- 6个月DAS28缓解率/DAPSA≤4缓解率分别为56%/27%(LUNDEX调整后45%/22%)。
- 6个月ACR20/50/70应答率分别为53%/38%/22%。
- 2009年后起始TNFi且符合CASPAR标准(n=1980)或基线≥1个肿胀关节(n=5803)者,留存率与应答率与总体相似。
关键数值与推荐
- DAS28缓解定义为DAS28<2.6;DAPSA缓解定义为DAPSA≤4。
- ACR20/50/70应答按相应改善标准计算,并做LUNDEX调整。
临床怎么用
- 真实世界数据提示生物制剂初治PsA患者起始TNFi后约半数6个月达DAS28缓解、约四分之三1年仍在用药,可作为临床预期参考。
- 注册库间结局异质性显著,解读留存与应答率时需考虑来源人群与基线差异。
局限性
- 基线特征在注册库间存在显著异质性,可能影响结局比较。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate TNF inhibitor (TNFi) retention and response rates in European biologic-naïve patients with PsA. METHODS: Prospectively collected data on PsA patients in routine care from 12 European registries were pooled. Heterogeneity in baseline characteristics between registries were explored (analysis of variance and pairwise comparison). Retention rates (Kaplan-Meier), clinical remission [28-joint count DAS (DAS28) <2.6; 28 joint Disease Activity index for Psoriatic Arthritis ⩽4] and ACR criteria for 20% improvement (ACR20)/ACR50/ACR70 were calculated, including LUNDEX adjustment. RESULTS: Overall, 14 261 patients with PsA initiated a first TNFi. Considerable heterogeneity of baseline characteristics between registries was observed. The median 12-month retention rate (95% CI) was 77% (76, 78%), ranging from 68 to 90% across registries. Overall, DAS28/28 joint Disease Activity index for Psoriatic Arthritis remission rates at 6 months were 56%/27% (LUNDEX: 45%/22%). Six-month ACR20/50/70 responses were 53%/38%/22%, respectively. In patients initiating a first TNFi after 2009 with registered fulfilment of ClASsification for Psoriatic ARthritis (CASPAR) criteria (n = 1980) or registered one or more swollen joint at baseline (n = 5803), the retention rates and response rates were similar to those found overall. CONCLUSION: Approximately half of >14 000 patients with PsA who initiated first TNFi treatment in routine care were in DAS28 remission after 6 months, and three-quarters were still on the drug after 1 year. Considerable heterogeneity in baseline characteristics and outcomes across registries was observed. The feasibility of creating a large European database of PsA patients treated in routine care was demonstrated, offering unique opportunities for research with real-world data.
引用
- Brahe CH, Ørnbjerg LM, Jacobsson L, et al. Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA. Rheumatology (Oxford). 2020. PMID: 31665497. doi:10.1093/rheumatology/kez427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。